Gestational Diabetes Market Size was valued at USD 8.63 Billion in 2023. The Global Gestational Diabetes industry is projected to grow from USD 9.27 Billion in 2024 to USD 16.54 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 8.10% during the forecast period (2024 - 2032). Diabetes is a metabolic disorder in which the body glucose level is elevated. Gestational diabetes is a temporary or permanent form of diabetes in which the body daoes not produce adequate amounts of insulin to regulate sugar during pregnancy.
It may also be called glucose intolerance or carbohydrate intolerance. According to the International Diabetes Federation in 2016, it was estimated that 420 million adult population is suffering from diabetes which is increasing at the rate of 8.4% and is expected to reach 625 million by 2040. According to the American Pregnancy Association, approximately 2-5% of pregnant women develop gestational diabetes; this number may increase to 7-9% of mothers who are more likely to have risk factors.
Increasing prevalence of the gestational diabetic population is the major driving factor for the growth of the gestational diabetes market. Moreover, increasing obese population, increasing healthcare expenditure, and strong encouragement from the government have also contributed to the growth of the gestational diabetes market. According to research, smoking increases the possibility of diabetes; more than 60% of the global population smokes, this has increased the risk of diabetes and contributed to the growth of the gestational diabetes market. However, lack of awareness among people and cost issues may lead to restrain the growth of the market.
Intended Audience
The gestational diabetes market is segmented on the basis of types, administration, treatment, and end users.
On the basis of types, the gestational diabetes market is segmented into type A1, type A2 and others.
On the basis of administration, the gestational diabetes market is categorised into oral, intravenous, and other.
On the basis of treatment, the gestational diabetes market is segmented into monitoring, drug treatment, and non-pharmacological treatment. Monitoring is further segmented into urinary glucose testing, oral glucose tolerance test, and others. Drug treatment is subsegmented into insulin, sensitizers, SGLT-2 inhibitors, alpha-glucosidase inhibitors, and others
On the basis of end users, the gestational diabetes market is segmented into hospital, retail pharmacy and other.
America dominates the gestational diabetes market owing to large patient population. Apart from this, increasing number of obese people, changing lifestyle and increasing healthcare expenditure have boosted the growth of the market in America. According to the Centers for Disease Control and Prevention (2014), 73.5 million adults in the US were diagnosed with high cholesterol level. Increasing cholesterol level and smoking increases the possibility of causing diabetes. Additionally, increasing awareness among the people regarding different monitoring procedures and well-developed technology has also contributed to the growth of the market.
Europe is the second largest gestational diabetes market, which is followed by Asia Pacific. Huge smoking population, availability of funds for research, and government support for research & development will drive the market.
Asia Pacific is the fastest growing region for the market due to the presence of a huge patient population, continuously developing economies, and increasing need for the better treatment.
On the other hand, the Middle East & Africa has the least share in the gestational diabetes market due to presence of poor economy especially in Africa region. Majority of the market of this region is hold by Middle East due to well-developed healthcare sector and huge healthcare expenditure.
Key Players for Gestational Diabetes Market
| Report Attribute/Metric | Details |
| Market Size | USD 16.54 Billion |
| Compound Annual Growth Rate (CAGR) | 8.10% (2024-2032) |
| Base Year | 2021 |
| Market Forecast Period | 2024-2032 |
| Historical Data | 2018 & 2020 |
| Market Forecast Units | Value (USD million) |
| Report Coverage | Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Types, Administration, Treatment, and End Users |
| Geographies Covered | North America, Europe, Asia Pacific, and Rest of the World |
| Countries Covered | The U.S, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
| Key Companies Profiled | Antares Pharma (US), INJEX Pharma AG (Germany), 3M (US), Eli Lilly (US), Biocon (US), Sunpharma (India), Sanofi (France), Novo Nordisk (Denmark), Abbott (US), AstraZeneca (UK), Novartis (Switzerland), Daiichi Sankyo (Japan), Boehringer Ingelheim (Germany), Merck & Co. (US), Pfizer (US), Akros Pharma (US), Amgen (US), Adocia (France), Peptron (South Korea), and Takeda (Japan). |
| Key Market Opportunities | New product launches and R&D Amongst major key Players |
| Key Market Drivers | Increasing prevalence of the gestational diabetic population Increasing obese population Increasing healthcare expenditure Strong encouragement from the government |
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
